The three platform deals are long-term bets, but broaden Genentech’s drug discovery capabilities, particularly in small-molecule R&D. The Convelo deal focuses on the development of novel drug ...

BenevolentAI has entered a two-year agreement with the MRC Technology to investigate new small molecule and antibody drug candidates. The UK-based artificial intelligence company has teamed up ...